Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target

Author(s): Luca Miele, Giuseppe Marrone, Cristiano Lauritano, Consuelo Cefalo, Antonio Gasbarrini, Chris Day, Antonio Grieco

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 29 , 2013

Become EABM
Become Reviewer
Call for Editor


There is increasing evidence for a correlation between intestinal microbiota, bacterial translocation and hepatic steatosis. Intestinal microbiota affects nutrient absorption and energy homeostasis. Altered intestinal permeability may favor the passage of bacteriaderived compounds into systemic circulation, causing a systemic inflammatory state, characteristic of the metabolic syndrome. The interaction between intestinal permeability and luminal bacteria is involved in the pathogenesis and evolution of non-alcoholic liver disease. Microbiota pharmacological modulation could be a promising tool for a new therapeutical approach to non-alcoholic fatty liver disease.

Keywords: Gut-liver axis, intestinal permeability, insulin resistance, human microbiota, NAFLD, portal hypertension.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 June, 2013
Page: [5314 - 5324]
Pages: 11
DOI: 10.2174/1381612811319290011
Price: $65

Article Metrics

PDF: 43